2.45Open2.45Pre Close0 Volume1 Open Interest10.00Strike Price0.00Turnover708.37%IV0.26%PremiumDec 13, 2024Expiry Date2.43Intrinsic Value100Multiplier1DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.6318Delta0.1034Gamma2.40Leverage Ratio-0.4564Theta-0.0003Rho-1.52Eff Leverage0.0019Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet